Natalie C. Holles
CIK 1580111 · See Remarks · last filed 2026-06-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$8.89M
Companies
8
Total Filings
42
Lifetime Open-Market Net
-$411.5K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LONA | Director | — | $7.50 | — | $0 | 2 | 2026-06-24 |
| AURA | See Remarks | 1,153,962 | $7.70 | $8.89M | $0 | 1 | 2026-05-19 |
| Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Director | 0 | $21.53 | $0 | $0 | 6 | 2026-04-23 |
| Third Harmonic Bio, Inc. (THRD) Delisted | CEO | 1,218,836 | $5.38 | $6.56M | -$411.5K | 7 | 2025-01-17 |
| Rubius Therapeutics, Inc. (RUBY) Delisted | Director | — | $0.08 | — | $0 | 4 | 2022-05-13 |
| Allakos Inc. (ALLK) Delisted | Director | — | $0.33 | — | $0 | 2 | 2021-10-14 |
| BOLD | President and COO | 0 | $2.82 | $0 | $0 | 12 | 2020-01-15 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | SVP, Business Development | 0 | — | — | $0 | 6 | 2015-05-08 |
Recent Filings · Page 3 of 5
42 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-05-13 | Rubius Therapeutics, Inc. (RUBY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-01-06 | Allakos Inc. (ALLK) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-05-26 | Rubius Therapeutics, Inc. (RUBY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-01-15 | BOLD | Mixed | −104,439 | -$6.27M | EDGAR |
| 2019-12-16 | BOLD | Mixed | +49,735 | -$3.93M | EDGAR |
| 2019-12-09 | BOLD | Tax (F) | −505 | -$29.9K | EDGAR |
| 2019-09-09 | BOLD | Tax (F) | −505 | -$15.7K | EDGAR |
| 2019-06-07 | BOLD | Tax (F) | −1,009 | -$37.6K | EDGAR |
| 2019-04-01 | Rubius Therapeutics, Inc. (RUBY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-02-08 | BOLD | Grant (A) | +23,333 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.